We are involved in all of the phases of the health product and/or service life cycle (medicine, medical devices, raw materials for pharmaceutical use, in vitro diagnostic devices, biological and biotechnological products, cosmetics, patient health data, clinical trials, e-health, etc.) and for all French and international operators (pharmaceutical laboratories, medical equipment manufacturers, public or private research institutes, academic stakeholders, biotechnology companies, investors, service providers, competitiveness clusters, etc.).
We assist our clients in three strategic dimensions:
Our assets? Lawyers coming from the pharmaceutical industry or from the field ofmedical equipment finance and senior public administration, a strong relationships with administrative bodies in the field of health, new technologies and personal data protection (CNIL) or professional organizations (including LEEM) and a network of international clients and partners which enable us to remain at the forefront of developments in the health sector.
Subscription:
On this topic and many others, please let us know your main areas of interest
to receive selected information.
De Gaulle Fleurance announces the launch of SPATIO, a think tank dedicated to the space sector
During an event bringing together all the players in the sector (manufacturers, finan...
De Gaulle Fleurance advises Andera Partners in raising €15 million to finance Inthy’s growth
De Gaulle Fleurance advises private equity firm Andera Partners and its Andera Smart ...